1696 (1696) Fair Value & Analysis

Healthcare · Market cap HK$1.1B

1 1696 1696 · HK

PriceHK$2.26

Fair ValueHK$0.8900

Upside-60.6%

Quality46/100

Watch 1696 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.6000 – HK$1.12

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −17.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.24 – HK$7.67 · fair‑value band HK$0.6000 – HK$1.12 · the HK$2.26 price screens above the HK$0.8900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1696 (1696) currently trades at HK$2.26, while our model-based Fair Value estimate is HK$0.8900 — implying the stock looks roughly 60.6% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1696 generated revenue of HK$365M at a net margin of 5.2%. Revenue grew 10.8% year over year. It earns a return on equity of 5.1%. The balance sheet holds a net cash position of HK$19.2M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$365M

Revenue growth (YoY) +10.8%

Net margin 5.2%

Return on equity 5.1%

Free cash flow HK$6.8M FY2025

P/E ratio 7.1

More key figures

Operating margin 9.2%

EPS (TTM) HK$0.0100

Dividend yield 0.5%

EPS growth (YoY) -11.0%

Net cash HK$19.2M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1696 reported revenue of HK$365M in FY2025 versus HK$294M in FY2021, a compound +5.6%/yr. Reported net income was HK$19.0M in FY2025, compounding −11.7%/yr from FY2021.

Revenue +5.6%/yr

FY21 HK$294M

FY22 HK$354M

FY23 HK$359M

FY24 HK$349M

FY25 HK$365M

Net income −11.7%/yr

FY21 HK$31.2M

FY22 HK$40.2M

FY23 HK$31.5M

FY24 HK$25.1M

FY25 HK$19.0M

Is 1696 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1696 (1696) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$2.26 — about −61% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1696?

Our model-based fair value for 1696 is HK$0.8900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.26.

What is the quality score of 1696?

1696 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1696 (1696)?

1696 reported trailing-twelve-month revenue of about HK$365M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1696?

The net profit margin of 1696 is about 5.2%, meaning it keeps roughly 5.2% of revenue as net income. Based on the latest reported figures.

Does 1696 pay a dividend?

1696 currently shows a dividend yield of about 0.53% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.